US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

AstraZeneca PLC - American Depositary Shares (NY:AZN)

171.49 -1.08 (-0.63%)
Official Closing Price Updated: 7:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,691,385
Open 171.28
Bid (Size) 168.50 (100)
Ask (Size) 172.89 (500)
Prev. Close 172.57
Today's Range 169.51 - 171.75
52wk Range 153.41 - 212.71
Shares Outstanding N/A
Dividend Yield 0.54%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire

Performance

52-Week Range 19.4% below 52-week high
171.49
153.4152W Low 212.7152W High
1 Week 1.4% below 1-week high
163.911W Low 173.911W High

AstraZeneca PLC - American Depositary Shares (AZN) traded between $153.41 and $212.71 over the past 52 weeks and last traded at $171.49, 19.4% below its 52-week high. Over the past week it ranged between $163.91 and $173.91.

Past 12 Months
+4.6%
+5.0%
+1.3%
-9.6%
-9.0%
-9.0%
1W +$7.54
1M +$8.16
3M +$2.23
6M -$18.26
YTD -$16.92
1Y -$16.92

AZN was -9.0% over the past year, -9.6% over six months, -9.0% year to date, +4.6% in the last week.

12 Months vs Market
AZN
-9.0%
DIA
+11.6%
SPY
+13.1%
QQQ
+15.4%
IWM
+11.9%

Over the past 12 months AZN returned -9.0% versus DIA (Dow) +11.6%, SPY (S&P 500) +13.1%, QQQ (Nasdaq 100) +15.4% and IWM (Russell 2000) +11.9%.

Volume & Liquidity 1.08× 3-mo avg
Today 3,691,385 3-mo avg 3.4M
1W
3.1M
1M
2.9M
3M
3.4M
6M
2.8M
YTD
2.6M
1Y
2.6M

AZN most recently traded 3,691,385 shares against a 3-month average daily volume of 3.4M.

More News

Read More
News headline image
ZEGFROVY® (sunvozertinib) now available in the US for patients with previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations
From AstraZeneca
Via Business Wire
News headline image
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech? ↗
Via The Motley Fool
News headline image
TEZSPIRE positive results from Phase III CROSSING trial in eosinophilic esophagitis including symptom improvement, histologic and endoscopic remission presented at United European Gastroenterology Week
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca HPP Drug Shows Gains Despite Missing Key Phase III Endpoint ↗
Via MarketBeat
Topics ETFs
News headline image
Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗
Via The Motley Fool
News headline image
2 Growth Stocks to Buy in October ↗
Via The Motley Fool
News headline image
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts
From AstraZeneca
Via Business Wire
News headline image
18 of 21 Analysts Still Think Alnylam Stock Is a Buy. Here's Why They're Right. ↗
Via The Motley Fool
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
News headline image
Alnylam's Sell-Off Looks Ugly -- but Wall Street Still Sees a Much Brighter Picture ↗
Via The Motley Fool
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears ↗
Via MarketBeat
Topics ETFs
News headline image
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
From AstraZeneca
Via Business Wire
News headline image
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
News headline image
Here's Why Ionis Pharmaceuticals' Steep Sell-off Was Overdone ↗
Via The Motley Fool
News headline image
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
From AstraZeneca
Via Business Wire
News headline image
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
From AstraZeneca
Via Business Wire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
From MarketNewsUpdates.com
Via GlobeNewswire

Frequently Asked Questions

Is AstraZeneca PLC - American Depositary Shares publicly traded?
Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
What exchange does AstraZeneca PLC - American Depositary Shares trade on?
AstraZeneca PLC - American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the New York Stock Exchange
What is the current price of AstraZeneca PLC - American Depositary Shares?
The current price of AstraZeneca PLC - American Depositary Shares is 171.49
When was AstraZeneca PLC - American Depositary Shares last traded?
The last trade of AstraZeneca PLC - American Depositary Shares was at 10/23/26 07:00 PM ET